Shenzhen Rhegen Biotechnology Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Shenzhen Rhegen Biotechnology Co., Ltd.
Chinese vaccine maker Recbio hopes an IPO in Hong Kong will bring investor attention to its mRNA COVID vaccine with potential against the Omicron variant.
The leader in China's homegrown mRNA COVID-19 vaccine effort expects a delay to key Phase III results, with analysts now expecting to see figures from the international portion of the study in early 2022.
- Contract Research Organization-CRO
- Research, Analytical Equipment & Supplies
- Antisense, Oligonucleotides
- Drug Discovery Tools